Dicerna CEO explains how a desire to expand collaborations turned into a potential acquisition
Novo Nordisk's possible billion-dollar takeover of US-based Dicerna, which was announced last week, stems from a suggestion to extend their partnership, CEO at Dicerna Douglas Fambrough tells MedWatch, and Novo Nordisk confirms.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
What could end up being Novo Nordisk's biggest deal in recent times actually began as a wish to expand the collaboration with the US-based Dicerna around three months ago, says the latter company's CEO Douglas Fambrough.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Huge acquisition scores Novo Nordisk an FDA-ready treatment
For subscribers
